EMERGENT BIOSOLUTIONS INC (EBS) Stock Fundamental Analysis
USA - NYSE:EBS - US29089Q1058 - Common Stock
10.1 USD
-0.01 (-0.1%)
10.02 USD
-0.08 (-0.79%)
EBS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. EBS has only an average score on both its financial health and profitability. EBS has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year EBS was profitable.
EBS had a positive operating cash flow in the past year.
In multiple years EBS reported negative net income over the last 5 years.
In multiple years EBS reported negative operating cash flow during the last 5 years.
1.2 Ratios
EBS has a Return On Assets of 5.20%. This is amongst the best in the industry. EBS outperforms 91.93% of its industry peers.
The Return On Equity of EBS (13.03%) is better than 94.00% of its industry peers.
With an excellent Return On Invested Capital value of 6.57%, EBS belongs to the best of the industry, outperforming 93.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.2% | ||
| ROE | 13.03% | ||
| ROIC | 6.57% |
ROA(3y)-20.7%
ROA(5y)-8.82%
ROE(3y)-57.28%
ROE(5y)-27.44%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
EBS has a better Profit Margin (9.62%) than 91.93% of its industry peers.
EBS's Operating Margin of 13.96% is amongst the best of the industry. EBS outperforms 93.25% of its industry peers.
EBS's Gross Margin of 54.58% is fine compared to the rest of the industry. EBS outperforms 76.55% of its industry peers.
In the last couple of years the Gross Margin of EBS has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.96% | ||
| PM (TTM) | 9.62% | ||
| GM | 54.58% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.64%
GM growth 5Y-10.6%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so EBS is destroying value.
EBS has more shares outstanding than it did 1 year ago.
EBS has more shares outstanding than it did 5 years ago.
EBS has a worse debt/assets ratio than last year.
2.2 Solvency
EBS has an Altman-Z score of 1.59. This is a bad value and indicates that EBS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of EBS (1.59) is better than 66.23% of its industry peers.
EBS has a debt to FCF ratio of 473.64. This is a negative value and a sign of low solvency as EBS would need 473.64 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 473.64, EBS belongs to the top of the industry, outperforming 89.49% of the companies in the same industry.
EBS has a Debt/Equity ratio of 1.14. This is a high value indicating a heavy dependency on external financing.
EBS has a Debt to Equity ratio of 1.14. This is in the lower half of the industry: EBS underperforms 77.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.14 | ||
| Debt/FCF | 473.64 | ||
| Altman-Z | 1.59 |
ROIC/WACC0.69
WACC9.53%
2.3 Liquidity
A Current Ratio of 5.76 indicates that EBS has no problem at all paying its short term obligations.
EBS's Current ratio of 5.76 is fine compared to the rest of the industry. EBS outperforms 60.98% of its industry peers.
EBS has a Quick Ratio of 3.15. This indicates that EBS is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.15, EBS perfoms like the industry average, outperforming 40.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.76 | ||
| Quick Ratio | 3.15 |
3. Growth
3.1 Past
EBS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 275.22%, which is quite impressive.
The Revenue for EBS has decreased by -29.91% in the past year. This is quite bad
Measured over the past years, EBS shows a decrease in Revenue. The Revenue has been decreasing by -1.15% on average per year.
EPS 1Y (TTM)275.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.63%
Revenue 1Y (TTM)-29.91%
Revenue growth 3Y-16.2%
Revenue growth 5Y-1.15%
Sales Q2Q%-21.34%
3.2 Future
Based on estimates for the next years, EBS will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.93% on average per year.
Based on estimates for the next years, EBS will show a small growth in Revenue. The Revenue will grow by 7.53% on average per year.
EPS Next Y767.9%
EPS Next 2Y-21.08%
EPS Next 3Y-46.24%
EPS Next 5Y16.93%
Revenue Next Year-26.82%
Revenue Next 2Y-8.09%
Revenue Next 3Y-15.25%
Revenue Next 5Y7.53%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 5.10 indicates a rather cheap valuation of EBS.
Based on the Price/Earnings ratio, EBS is valued cheaply inside the industry as 99.06% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 25.56, EBS is valued rather cheaply.
EBS is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.1 | ||
| Fwd PE | N/A |
4.2 Price Multiples
98.69% of the companies in the same industry are more expensive than EBS, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of EBS indicates a rather cheap valuation: EBS is cheaper than 89.68% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 384.88 | ||
| EV/EBITDA | 4.59 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
EBS has a very decent profitability rating, which may justify a higher PE ratio.
EBS's earnings are expected to decrease with -46.24% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y-21.08%
EPS Next 3Y-46.24%
5. Dividend
5.1 Amount
EBS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
10.1
-0.01 (-0.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners70.25%
Inst Owner Change4.32%
Ins Owners2.76%
Ins Owner Change-1.37%
Market Cap538.84M
Revenue(TTM)788.90M
Net Income(TTM)75.90M
Analysts74.29
Price Target13.77 (36.34%)
Short Float %15.89%
Short Ratio7.12
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)553.46%
Min EPS beat(2)132.33%
Max EPS beat(2)974.59%
EPS beat(4)4
Avg EPS beat(4)319.17%
Min EPS beat(4)59.77%
Max EPS beat(4)974.59%
EPS beat(8)6
Avg EPS beat(8)233.65%
EPS beat(12)6
Avg EPS beat(12)57.5%
EPS beat(16)8
Avg EPS beat(16)-95.56%
Revenue beat(2)1
Avg Revenue beat(2)6.63%
Min Revenue beat(2)-4.69%
Max Revenue beat(2)17.94%
Revenue beat(4)2
Avg Revenue beat(4)-2.65%
Min Revenue beat(4)-24.3%
Max Revenue beat(4)17.94%
Revenue beat(8)4
Avg Revenue beat(8)6.03%
Revenue beat(12)8
Avg Revenue beat(12)11.69%
Revenue beat(16)10
Avg Revenue beat(16)8.03%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-47.62%
EPS NQ rev (3m)-52.17%
EPS NY rev (1m)72.27%
EPS NY rev (3m)186.71%
Revenue NQ rev (1m)-3.33%
Revenue NQ rev (3m)-5.99%
Revenue NY rev (1m)2.64%
Revenue NY rev (3m)-1.7%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.1 | ||
| Fwd PE | N/A | ||
| P/S | 0.68 | ||
| P/FCF | 384.88 | ||
| P/OCF | 41.45 | ||
| P/B | 0.93 | ||
| P/tB | 4.15 | ||
| EV/EBITDA | 4.59 |
EPS(TTM)1.98
EY19.6%
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)0.03
FCFY0.26%
OCF(TTM)0.24
OCFY2.41%
SpS14.79
BVpS10.92
TBVpS2.43
PEG (NY)0.01
PEG (5Y)N/A
Graham Number22.05
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.2% | ||
| ROE | 13.03% | ||
| ROCE | 8.31% | ||
| ROIC | 6.57% | ||
| ROICexc | 8.06% | ||
| ROICexgc | 13.89% | ||
| OM | 13.96% | ||
| PM (TTM) | 9.62% | ||
| GM | 54.58% | ||
| FCFM | 0.18% |
ROA(3y)-20.7%
ROA(5y)-8.82%
ROE(3y)-57.28%
ROE(5y)-27.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.64%
GM growth 5Y-10.6%
F-Score6
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.14 | ||
| Debt/FCF | 473.64 | ||
| Debt/EBITDA | 3.18 | ||
| Cap/Depr | 11.8% | ||
| Cap/Sales | 1.47% | ||
| Interest Coverage | 2.21 | ||
| Cash Conversion | 6.24% | ||
| Profit Quality | 1.84% | ||
| Current Ratio | 5.76 | ||
| Quick Ratio | 3.15 | ||
| Altman-Z | 1.59 |
F-Score6
WACC9.53%
ROIC/WACC0.69
Cap/Depr(3y)106.07%
Cap/Depr(5y)126.37%
Cap/Sales(3y)13.29%
Cap/Sales(5y)12.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)275.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.63%
EPS Next Y767.9%
EPS Next 2Y-21.08%
EPS Next 3Y-46.24%
EPS Next 5Y16.93%
Revenue 1Y (TTM)-29.91%
Revenue growth 3Y-16.2%
Revenue growth 5Y-1.15%
Sales Q2Q%-21.34%
Revenue Next Year-26.82%
Revenue Next 2Y-8.09%
Revenue Next 3Y-15.25%
Revenue Next 5Y7.53%
EBIT growth 1Y195.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year347.11%
EBIT Next 3Y55.51%
EBIT Next 5Y39.09%
FCF growth 1Y100.65%
FCF growth 3Y-28.05%
FCF growth 5Y-17.04%
OCF growth 1Y108.93%
OCF growth 3Y-43.25%
OCF growth 5Y-20.77%
EMERGENT BIOSOLUTIONS INC / EBS FAQ
Can you provide the ChartMill fundamental rating for EMERGENT BIOSOLUTIONS INC?
ChartMill assigns a fundamental rating of 4 / 10 to EBS.
What is the valuation status for EBS stock?
ChartMill assigns a valuation rating of 6 / 10 to EMERGENT BIOSOLUTIONS INC (EBS). This can be considered as Fairly Valued.
What is the profitability of EBS stock?
EMERGENT BIOSOLUTIONS INC (EBS) has a profitability rating of 6 / 10.
What is the expected EPS growth for EMERGENT BIOSOLUTIONS INC (EBS) stock?
The Earnings per Share (EPS) of EMERGENT BIOSOLUTIONS INC (EBS) is expected to grow by 767.9% in the next year.